Olema Pharmaceuticals (NASDAQ:OLMA) Given “Buy” Rating at HC Wainwright

Olema Pharmaceuticals (NASDAQ:OLMA)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a report released on Wednesday,Benzinga reports. They presently have a $30.00 price target on the stock. HC Wainwright’s price objective suggests a potential upside of 346.43% from the stock’s current price.

Olema Pharmaceuticals Stock Down 20.1 %

Shares of OLMA stock opened at $6.72 on Wednesday. The firm has a market capitalization of $385.04 million, a price-to-earnings ratio of -3.07 and a beta of 1.92. The stock has a fifty day moving average of $10.80 and a 200 day moving average of $11.88. Olema Pharmaceuticals has a 52 week low of $6.50 and a 52 week high of $16.77.

Insider Activity

In other news, Director Cyrus Harmon sold 8,256 shares of the firm’s stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $9.37, for a total value of $77,358.72. Following the completion of the transaction, the director now owns 772,277 shares in the company, valued at $7,236,235.49. This trade represents a 1.06 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Sean Bohen sold 52,328 shares of Olema Pharmaceuticals stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $9.37, for a total value of $490,313.36. Following the sale, the chief executive officer now owns 298,836 shares in the company, valued at $2,800,093.32. This represents a 14.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 73,036 shares of company stock valued at $684,472. Corporate insiders own 19.40% of the company’s stock.

Institutional Trading of Olema Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Conway Capital Management Inc. bought a new stake in Olema Pharmaceuticals during the third quarter worth about $119,000. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Olema Pharmaceuticals by 67.6% during the third quarter. China Universal Asset Management Co. Ltd. now owns 11,014 shares of the company’s stock valued at $132,000 after purchasing an additional 4,442 shares during the last quarter. Portland Investment Counsel Inc. purchased a new position in shares of Olema Pharmaceuticals during the third quarter valued at approximately $143,000. SG Americas Securities LLC bought a new stake in shares of Olema Pharmaceuticals in the 3rd quarter worth approximately $156,000. Finally, Cubist Systematic Strategies LLC purchased a new stake in shares of Olema Pharmaceuticals in the 2nd quarter worth approximately $145,000. 91.78% of the stock is owned by hedge funds and other institutional investors.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.